HSBC lowered its price target on Regeneron Pharmaceuticals while maintaining a Buy rating amid a broader healthcare sector review.
HSBC reduced its price target for Regeneron Pharmaceuticals (NASDAQ:REGN) to $800 from $990, reaffirming a Buy rating on the stock. The adjustment was part of a broader healthcare sector update assessing relative strength for the second half of the year.
The firm identified therapeutics as offering attractive risk-adjusted opportunities and noted potential in life sciences tools and undervalued medical technology companies. REGN’s prior target stood at $990, reflecting a 19% reduction in the new estimate.
Regeneron recently secured regulatory submissions for cemdisiran in the U.S. and Europe, with FDA Priority Review expected to conclude by November 2026.